15
Participants
Start Date
February 15, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
Tecentriq 1200 MG in 20 ML Injection
One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
H3K27M peptide vaccine
The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
Imiquimod (5%)
One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
Clinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden, Dresden
Department of Neurosurgery with Pediatric Neurosurgery, Berlin
Neurooncology Department, University Hospital Essen, Essen
Clinical Neuro-Oncology Section, University Hospital Bonn (UKB), Bonn
Dr. Senckenberg Institute for Neurooncology, University Hospital Frankfurt, Frankfurt am Main
University Medical Center Mannheim, Department of Neurology, Mannheim
Department of Neurology and Polyclinic, Universitiy Clinic Heidelberg, Heidelberg
University Clinic Tuebingen, Neurological Clinic, Department of Neurology, Tübingen
Johannes Gutenberg University Mainz
OTHER
Charite University, Berlin, Germany
OTHER
Roche Pharma AG
INDUSTRY
German Cancer Aid
OTHER
German Cancer Research Center
OTHER